Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC

Fig. 3

Pulmonary delivery of INC280-PFCE NPs alters INC280 distribution behavior in orthotopic NSCLC model. A Schematic diagram of pulmonary delivery of the INC280-PFCE NPs. B At 8 h and 7 days post-pulmonary delivery of INC280-PFCE NPs, ex vivo fluorescence images of tumors and major organs were taken. C Quantified fluorescence intensities of the excised major organs at 8 h and 7 days post-pulmonary delivery (n = 3). D In vivo 19F-MRI at different times after pulmonary delivery of INC280-PFCE NPs. E Quantitative analysis of the in vivo tumor accumulation of INC280-PFCE NPs at different times (n = 3). F After 24 h of oral administration of INC280 and pulmonary delivery of INC280-PFCE NPs, the content of INC280 in tumors and major organs was analyzed by HPLC (n = 3). The results are presented as mean ± standard deviation. * P < 0.05, ** P < 0.01 and **** P < 0.0001

Back to article page

Molecular Cancer

ISSN: 1476-4598